




RealRate

# PHARMACEUTICAL 2019

Aravive Inc.  
Rank 205 of 363





RealRate

# PHARMACEUTICAL 2019

Aravive Inc.  
Rank 205 of 363



The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Aravive Inc. is the variable Net Income, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 31% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	58,030
Cost of Goods Sold	0
Intangible Assets	341
Liabilities, Current	1,937
Liabilities, Non-Current	0
Other Assets	11,067
Other Compr. Net Income	0
Other Expenses	2,429
Other Liabilities	7,588
Other Net Income	1,508
Other Revenues	1,371
Property and Equipment	32
Research and Development	49,388
Selling, General and Administrative Expense	27,395

Output Variable	Value in 1000 USD
Assets	69,470
Liabilities	9,525
Expenses	79,212
Revenues	1,371
Stockholders Equity	59,945
Net Income	-76,333
Comprehensive Net Income	-76,333
Economic Capital Ratio	68%